FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, [D.C.	20549
---------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]									ationship of Reportin at all applicable) Director Officer (give title below)		10% O		wner (specify
						3. Date of Earliest Transaction (Month/Day/Year) 04/15/2009									EVP Drug Innov.& Realiz, CSO				
130 WAVERLY STREET (Street)				- 4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								Indiv ne) X	vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person					
CAMBRIDGE MA 02139				_										Form f Persor		e thar	n One Repo	orting	
(City)	(S	tate)	(Zip)																
		Tab	le I - N	lon-Deri	vative	Sec	uriti	ies Ad	cquire	d, D	isposed c	f, or B	eneficia	lly	Owned	t			
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/					Execution Year) if any		cution Date,		ction Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Securi Benefi Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Trans		ported nsaction(s) str. 3 and 4)			(Instr. 4)
Common Stock 04/15/2			2009	09		M		2,400	A	\$9.69	9 13		2,070		D				
Common	Stock			04/15/2	2009				S ⁽¹⁾		2,400	D	\$26.98 ⁽⁾	2)(3)	129,670			D	
Common	Stock													3,463 I 401(401(k)	
		Т	able I								posed of converti			у О	wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execut if any	3A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerci Expiration Dat (Month/Day/Ye		ate	7. Title a Amount Securitie Underlyi Derivativ (Instr. 3	of es ng /e Security	De Se	. Price of eerivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares						
Stock	\$9.69	04/15/2009			M	M 2,400		(4))	03/16/2014	Commor	2,400	Γ	\$0	7,200		D		

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- $2. Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$26.98 \ (range \ \$26.64 \ to \ \$27.19).$
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

04/16/2009

In-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.